A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo

Journal of Neuroimmunology

Volumn 78, Issue 1-2, 1997, Pages 34-46

  Ashley, David M ^a   Sampson, John H ^a   Archer, Gary E ^a   Batra, Surinder K ^a   Bigner, Darell D ^a   Hale, Laura P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antigen processing; Neuroimmunology; Rodent; Tumor immunity; Vaccination

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR ANTIGEN; TUMOR VACCINE;

ALLOGRAFT; ANIMAL CELL; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CENTRAL NERVOUS SYSTEM TUMOR; CYTOTOXIC T LYMPHOCYTE; GENE TARGETING; IMMUNE RESPONSE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CENTRAL NERVOUS SYSTEM NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENETIC TECHNIQUES; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNIZATION; MICE; MUTATION; NEOPLASM TRANSPLANTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0030771380     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(97)00080-5     Document Type: Article

References (76)

1. Alt F., Rosenberg N., Lewis S., Thomas E., Baltimore D. Organization and reorganization of immunoglobulin genes in A-MULV-transformed cells: Rearrangement of heavy but not light chain genes. Cell. 27:1981;381-390.
2. Arnold D., Faath S., Rammensee H., Schild H. Cross-priming of minor histocompatibility antigen-specific cytotoxic T-cells upon immunization with the heat shock protein gp96. J. Exp. Med. 182:1995;885-889.
3. Batra S.K., Castelino-Prabhu S., Wikstrand C.J., Xiaopei Z., Humphrey P.A., Friedman H.S., Bigner D.D. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ. 6:1995;1251-1259.
4. Batra S.K., Rasheed B.K., Bigner S.H., Bigner D.D. Oncogenes and anti-oncogenes in human central nervous system tumors. Lab. Invest. 71:1994;621-637.
5. Bevan M.J. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 143:1976;1283-1288.
6. Bevan M.J. Antigen presentation to cytotoxic T-lymphocytes in vivo. J. Exp. Med. 182:1995;639-641.
7. Billingham R.E., Brent L., Medawar B.B. Quantitative studies on tissue transplantation immunity. II The origin, strength, and duration of actively and adoptively acquired immunity. Proc. R. Soc. London. B143:1954;58-80.
8. Blachere N.E., Udono H., Janetzki S., Li Z., Heike M., Srivastava P.K. Heat shock protein vaccines against cancer. J. Immunother. 14:1993;352-356.
9. Bullard D.E., Gillespie G.Y., Mahaley M.S., Bigner D.D. Immunobiology of human gliomas. Semin. Oncol. 13:1986;94-109.
10. Bullard D.E., Thomas D.G., Darling J.L., Wikstrand C.J., Diengdoh J.V., Barnard R.O., Bodmer J.G., Bigner D.D. A preliminary study utilizing viable HLA mismatched cultured glioma cells as adjuvant therapy for patients with malignant gliomas. Br. J. Cancer. 51:1985;283-289.
11. Carbone F.R., Bevan M.J. Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J. Exp. Med. 171:1990;377-387.
12. Chatenoud L. Allograft rejection: The role of the cytokine network. Eur. Cytokine Netw. 3:1992;509-513.
13. Coligan, J.E., Kruisbeek, A.M., Margulies, D.H., Shevach, E.M., Strober, W., 1994. Current Protocols in Immunology. Greene and Wiley-Interscience, New York.
14. Dal Canto M.C., Melvold R.W., Kim B.S., Miller S.D. Two models of multiple sclerosis: Experimental allergic encephalomyelitis (EAE) and Theiler's murine encephalomyelitis virus (TMEV) infection. A pathological and immunological comparison. Microsc. Res. Tech. 32:1995;215-229.
15. Davis F.G., Malinski N., Haenszel W., Chang J., Flannery J., Gershman S., Dibble R., Bigner D.D. Primary brain tumor incidence rates in four United States regions, 1985-1989: A pilot study. Neuroepidemiology. 15:1995;103-112.
16. Dent P.B., McCulloch P.B., Liao S.K., Stone B.R., Singal D.P. Heterogeneity of melanoma-associated antigens detected by sera from patients receiving adjuvant allogeneic tumor vaccine immunotherapy. Clin. Immunol. Immunopathol. 23:1982;379-391.
17. Dialynas D.P., Quan Z.S., Wall K.A., Pierres A., Quintans J., Loken M.R., Pierres M., Fitch F.W. Characterization of the murine T-cell surface molecule, designated L3T4, identified by the monoclonal antibody GK1.5: Similarity of L3T4 to the human Leu 3/T4 molecule. J. Immunol. 131:1983;2445-2451.
18. Dillman R.O., Nayak S.K., Beutel L. Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy. J. Immunother. 14:1993;65-69.
19. Elliott G.T., McLeod R.A., Perez J., Von Eschen K.B. Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma. Semin. Surg. Oncol. 9:1993;264-272.
20. Fakhrai H., Dorigo O., Shawler D.L., Lin H., Mercola D., Black K.L., Royston I., Sobol R.E. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc. Natl. Acad. Sci. USA. 93:1996;2909-2914.
21. Fidler I.J. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res. 35:1975;218-224.
22. Gelber C., Plaksin D., Vadai E., Feldman M., Eisenbach L. Abolishment of metastasis formation by murine tumor cells transfected with 'foreign' H-2K genes. Cancer Res. 49:1989;2366-2373.
23. Giuliano A.E., Sparks F.C., Patterson K., Spears I., Morton D.L. Adjuvant chemo-immunotherapy in stage II carcinoma of the breast. J. Surg. Oncol. 31:1986;255-259.
24. Glick R.P., Lichtor T., Kim T.S., Ilangovan S., Cohen E.P. Fibroblasts genetically engineered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo. Neurosurgery. 36:1995;548-555.
25. Green A.A., Pratt C., Webster R.G., Smith K. Immunotherapy of osteosarcoma patients with virus-modified tumor cells. Ann. N.Y. Acad. Sci. 277:1976;396-411.
26. Grooms G.A., Eilber F.R., Morton D.L. Failure of adjuvant immunotherapy to prevent central nervous system metastases in malignant melanoma patients. J. Surg. Oncol. 9:1977;147-153.
27. Huang A.Y., Golumbek P., Ahmadzadeh M., Jaffee E., Pardoll D., Levitsky H. Bone marrow-derived cells present MHC class I-restricted tumour antigens in priming of antitumour immune responses. Ciba Found. Symp. 187:1994;229-240.
28. Huang A.Y., Golumbek P., Ahmadzadeh M., Jaffee E., Pardoll D., Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 264:1994;961-965.
29. Humphrey P.A., Wong A.J., Vogelstein B., Friedman H.S., Werner M.H., Bigner D.D., Bigner S.H. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res. 48:1988;2231-2238.
30. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
31. Kelley V.R., Strom T.B. A paradigm 1994: The allograft response. Blood Purif. 13:1995;199-205.
32. Krams S.M., Ascher N.L., Martinez O.M. New immunologic insights into mechanisms of allograft rejection. Gastroenterol. Clin. North Am. 22:1993;381-400.
33. Kurpad S.N., Zhao X.G., Wikstrand C.J., Batra S.K., McLendon R.E., Bigner D.D. Tumor antigens in astrocytic gliomas. Glia. 15:1995;244-256.
34. Kurtzberg J., Hershfield M.S. Determinants of deoxyadenosine toxicity in hybrids between human T- and B-lymphoblasts as a model for the development of drug resistance in T-cell acute lymphoblastic leukemia. Cancer Res. 45:1985;1579-1586.
35. Livingston P.O., Takeyama H., Pollack M.S., Houghton A.N., Albino A., Pinsky C.M., Oettgen H.F., Old L.J. Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells. Int. J. Cancer. 31:1983;567-575.
36. Logan T.F., Shannon W., Bryant J., Kane P., Wolmark N., Posner M., Kirkwood J.M., Ernstoff M.S., Futrell J.W., Straw L.D.et al. Preparation of viable tumour cell vaccine from human solid tumours: Relationship between tumour mass and cell yield. Melanoma Res. 3:1993;451-455.
37. Lopez J.G., Chew S.J., Thompson H.W., Malter J.S., Insler M.S., Beuerman R.W. EGF cell surface receptor quantitation on ocular cells by an immunocytochemical flow cytometry technique. Invest. Ophthalmol. Vis. Sci. 33:1992;2053-2062.
38. Merlino G.T., Ishii S., Whang-Peng J., Knutsen T., Xu Y.H., Clark A.J., Stratton R.H., Wilson R.K., Ma D.P., Roe B.A.et al. Structure and localization of genes encoding aberrant and normal epidermal growth factor receptor RNAs from A431 human carcinoma cells. Mol. Cell Biol. 5:1985;1722-1734.
39. Miller G.A., Pontes J.E., Huben R.P., Goldrosen M.H. Humoral immune response of patients receiving specific active immunotherapy for renal cell carcinoma. Cancer Res. 45:1985;4478-4482.
40. Mitchell M.S. Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. J. Clin. Oncol. 7:1989;1701-1709.
41. Mitchell M.S., Harel W., Kan-Mitchell J., LeMay L.G., Goedegebuure P., Huang X.Q., Hofman F., Groshen S. Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results and possible mechanisms of action. Ann. N.Y. Acad. Sci. 690:1993;153-166.
42. Murphy J.B., Sturm E. Conditions determining transplantability of tissues in the brain. J. Exp. Med. 38:1923;183-197.
43. Nabel G.J., Nabel E.G., Yang Z.Y., Fox B.A., Plautz G.E., Gao X., Huang L., Shu S., Gordon D., Chang A.E. Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans. Proc. Natl. Acad. Sci. USA. 90:1993;11307-11311.
44. Neidhart J.A., Murphy S.G., Hennick L.A., Wise H.A. Active specific immunotherapy of stage IV renal carcinoma with aggregated tumor antigen adjuvant. Cancer. 46:1980;1128-1134.
45. Oratz R., Cockerell C., Speyer J.L., Harris M., Roses D., Bystryn J.C. Induction of tumor-infiltrating lymphocytes in human malignant melanoma metastases by immunization to melanoma antigen vaccine. J. Biol. Response Mod. 8:1989;355-358.
46. Ostrand-Rosenberg S., Roby C., Clements V.K., Cole G.A. Tumor-specific immunity can be enhanced by transfection of tumor cells with syngeneic MHC-class-II genes or allogeneic MHC-class-I genes. Int. J. Cancer. 6 (Suppl.):1991;61-68.
47. Plaksin D., Gelber C., Eisenbach L. H-2Db gene transfer into highly metastatic D122 cells results in tumor rejection in allogeneic recipients, but does not affect metastasis in syngeneic recipients. Implications for mechanisms of allorejection. Int. J. Cancer. 52:1992;771-777.
48. Plautz G.E., Yang Z.Y., Wu B.Y., Gao X., Huang L., Nabel G.J. Immunotherapy of malignancy by in vivo gene transfer into tumors (see comments). Proc. Natl. Acad. Sci. USA. 90:1993;4645-4649.
49. Restifo, P.R., Wunderlich, J.R., 1995. In: De Vita, V.T., Hellman, S., Rosenberg, S.A. (Eds.), Biology of Cellular Immune Responses. Biologic Therapy of Cancer. J.B. Lippincott, Philadelphia, PA, pp. 3-39.
50. Ridley A., Cavanagh J.B. Lymphocytic infiltration in gliomas: Evidence of possible host resistance. Brain. 94:1971;117-124.
51. Roake J.A., Austyn J.M. The role of dendritic cells and T-cell activation in allograft rejection. Exp. Nephrol. 1:1993;90-101.
52. Sampson J.H., Archer G.E., Ashley D.M., Hale L.P., Dranoff G., Bigner D.D. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell mediated immunity against tumors located in the immunologically privileged central nervous system. Proc. Natl. Acad. Sci. USA. 93:1996;10399-10404.
53. Sarmiento M., Glasebrook A.L., Fitch F.W. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T-cell-mediated cytoloysis in the absence of complement. J. Immunol. 125:1980;2665-2672.
54. Scheinberg L.C., Levy A., Edelman F. Is the brain an immunologically privileged site? 2. Studies in induced host resistance to transplantable mouse glioma following irradiation of prior implants. Arch. Neurol. 13:1965;283-286.
55. Scheinberg L.C., Suzuki K., Edelman F., Davidoff L.M. Studies in immunization against a transplantable cerebral mouse glioma. J. Neurosurg. 20:1963;312-317.
56. Serano R.D., Pegram C.N., Bigner D.D. Tumorigenic cell culture lines from a spontaneous VM/Dk murine astrocytoma (SMA). Acta Neuropathol. 51:1980;53-64.
57. Shirai Y. Transplantations of rat sarcomas in adult heterogeneous animals. Jpn. Med. World. 1:1921;14-15.
58. Spertini O., Kansas G.S., Reimann K.A., Mackay C.R., Tedder T.F. Function and evolutionary conservation of distinct epitopes on the leukocyte adhesion molecule-1 (TQ-1, Leu-8) that regulate leukocyte migration. J. Immunol. 147:1991;942-949.
59. Srivastava P.K., Udono H. Heat shock protein-peptide complexes in cancer immunotherapy. Curr. Opin. Immunol. 6:1994;728-732.
60. Strauss M.M., Bigner S.H., Bigner D.D. Experimental allergic encephalomyelitis in Lewis rats bearing avian sarcoma virus-induced brain tumors. J. Neuroimmunol. 2:1982;283-294.
61. Swanborg R.H. Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease. Clin. Immunol. Immunopathol. 77:1995;4-13.
62. Takeuchi J., Barnard R.O. Perivascular lymphocytic cuffing in astrocytomas. Acta Neuropathol. 35:1976;265-271.
63. Takeyama H., Watanabe T., Livingston P.O. Vaccine therapy of malignant melanoma. II. Serological evaluation of the immune responses to the injection using allogeneic melanoma cell vaccine. Gan To Kagaku Ryoho. 10:1983;1624-1633.
64. Tedder T.F., Penta A.C., Levine H.B., Freedman A.S. Expression of the human leukocyte adhesion molecule, LAM1. Identity with the TQ1 and Leu-8 differentiation antigens. J. Immunol. 144:1990;532-540.
65. Toes R.E.M., Blom R.J.J., van der Voort E., Offringa R., Melief J.M., Kast W.M. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res. 56:1996;3782-3787.
66. Udono H., Srivastava P.K. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J. Immunol. 152:1994;5398-5403.
67. Ullrich S.J., Robinson E.A., Law L.W., Willingham M., Appella E. A mouse tumor-specific transplantation antigen is a heat shock-related protein. Proc. Natl. Acad. Sci. USA. 83:1986;3121-3125.
68. Walker W.S. Origins of macrophage diversity: Functional and phenotypic analysis of cloned populations of mouse splenic macrophages. Cell. Immunol. 107:1987;417-432.
69. Wallack M.K., Sivanandham M., Balch C.M., Urist M.M., Bland K.I., Murray D., Robinson W.A., Flaherty L.E., Richards J.M., Bartolucci A.A.et al. A phase III randomized, double-blind multi-institutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer. 75:1995;34-42.
70. Watschinger B. How T-cells recognize alloantigen: Evidence for two pathways of allorecognition. Nephrol. Dial. Transplant. 10:1995;1556-1558.
71. Whiteside M.G., Cauchi M.N., Paton C., Stone J. Chemoimmunotherapy for maintenance in acute myeloblastic leukemia. Cancer. 38:1976;1581-1586.
72. Wikstrand C.J., Hale L.P., Batra S.K., Hill M.L., Humphrey P.A., Kurpad S.N., McLendon R.E., Moscatello D., Pegram C.N., Reist C.J.et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 55:1995;3140-3148.
73. Wikstrand C.J., Stanley S.D., Humphrey P.A., Pegram C.N., Archer G.E., Kurpad S., Shibuya M., Bigner D.D. Investigation of a synthetic peptide as immunogen for a variant epidermal growth factor receptor associated with gliomas. J. Neuroimmunol. 46:1993;165-173.
74. Wiseman C.L. Inflammatory breast cancer: 10-year follow-up of a trial of surgery, chemotherapy, and allogeneic tumor cell/BCG immunotherapy. Cancer Invest. 13:1995;267-271.
75. Wong A.J., Bigner S.H., Bigner D.D., Kinzler K.W., Hamilton S.R., Vogelstein B. Increased exypression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc. Natl. Acad. Sci. USA. 84:1987;6899-6903.
76. Wood G.W., Morantz R.A. Immunohistologic evaluation of the lymphoreticular infiltrate of human central nervous system tumors. J. Natl. Cancer Inst. 62:1979;485-491.